Preventing mother-to-child transmission of HIV in developing countries: Recent developments and ethical implications

Reproductive Health Matters

Volumn 8, Issue 15, 2000, Pages 87-92

  Hankins, Catherine ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Antiretroviral therapy; Mother to child HIV transmission; Nevirapine; Voluntary testing and counselling

Indexed keywords

NEVIRAPINE;

ARTIFICIAL MILK; BREAST FEEDING; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL ETHICS; MOTHER CHILD RELATION; NEWBORN; PREGNANCY; PRIORITY JOURNAL; REVIEW;

EID: 0034078990     PISSN: 09688080     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-8080(00)90009-0     Document Type: Article

References (23)

1. UNAIDS Joint United Nations Programme on HIV/AIDS. AIDS epidemic update: December 1999.
2. World Health Organisation. Recommendations on the safe and effective use of short-course ZDV for prevention of mother-to-child transmission of HIV. Weekly Epidemiological Record. 1998; 41:313-20, Geneva.
3. Cartoux M, Meda N, Van de Perre P et al and the Ghent International Working Group on Mother-to-Child Transmission of HIV. Acceptability of voluntary HIV testing by pregnant women in developing countries: an international survey. AIDS 1998; 12:2489-93.
4. Connor EM, Sperling RS, Gelber R et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. New England Journal of Medicine 1994; 331:1173-80.
5. Wiktor SZ, Ekpini E, Karon JM et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte D'Ivoire: a randomised trial. Lancet 1999; 353:781-85.
6. Dabis F, Msellati P, Meda N et al for the DITRAME Study Group. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999; 353:786-92.
7. DITRAME ANRS 049 Study Group. 15-month efficacy of maternal oral zidovudine to decrease vertical transmission of HIV-1 in breastfed African children. Lancet 1999; 353:2050-51.
8. Shaffer N, Chuachoowong R, Mock P et al on behalf of the Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999; 353:773-80.
9. Guay L A, Musoke P, Fleming T et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda : HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
10. Mofenson LM. Short-course zidovudine for prevention of perinatal infection. Lancet 1999; 354:766-67.
11. Aka-Dago-Akribi HA, Desgrées du Loû A, Msellati P et al. Issues surrounding reproductive choices for women living with HIV in Abidjan, Côte d'Ivoire. Reproductive Health Matters 1999; 7:20-29.
12. Canadian HIV/AIDS Legal Network. Rapid HW Screening at the Point of Care: Legal and Ethical Questions. Montreal, Canada 2000. www.aidslaw.ca
13. Marseille E, Kahn J G, Mmiro F et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet 1999; 354:803-09.
14. Musoke P, Guay L A, Bagenda D et al. A phase I/II study of the safety and pharmacokinetics of neviparine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13(4):479-86.
15. Havlir D V, Eastman S, Gamst A, Richman D. Nevirapine-resistant human immunodeficiency virus : kinetics of replication and estimated prevalence in untreated patients. Journal of Virology. 1996; 70:7894-99.
16. Becker-Pergola G, Guay L, Mmiro F et al. Selection of the K103N nevirapine resistance mutation in Ugandan women receiving NVP prophylaxis to prevent HIV-1 Vertical transmision (HIVNET-006). 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, 30 Jan - 2 Feb 2000.
17. World Health Organization. Use of nevirapine to reduce mother-to-child transmission of HIV (MTCT). WHO Review of Reported Drug Resistance. Geneva, 24 March 2000. www.who.int/reproductive-health/publications/ nevirapine/report.htm
18. Hirsch MS, Conway B, D'Aquila RT et al for the International AIDS Society-USA Panel. Antiretroviral drug resistance testing in adults with HIV infection. Implications for clinical management. JAMA. 1998; 279:1984-91.
19. Giles RE, Perry KR, Parry JV. Simple/rapid test devices for anti-HIV screening: do they come up to the mark? Journal of Medical Virology 1999; 59:104-09.
20. Downing RG, Otten RA, Marum E et al. Optimizing the delivery of HIV counselling and testing services: the Uganda experience using rapid HIV-1 antibody test algorithms. Journal of Acquired Immune Deficiency Syndrome & Human Retrovirol 1998; 18:384-88.
21. BBC News Online. January 2000. http://news.bbc.co.uk/hi/ english/world.
22. Gannon JC. The global infectious disease threat and its implications for the USA. www.cia.gov/cia/publications/ nie/report/nie99-17d.html.
23. Berer M. Reducing perinatal HIV transmission in developing countries in the context of antenatal and delivery care and breastfeeding: Supporting infant survival by supporting women's survival. Bulletin of WHO 1999; 77(11):871-77.